COMP <GO>
TCMD vs MRK // RSI-14 & 200D SMA MOMENTUM
Tactile Systems Technology Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: TCMD 7
— MRK 6
▲ RSI-14 & 200D SMA MOMENTUM LEADER: TCMD
LAST: $23.04 (-5.22%) • MKT CAP: $550.7M
rsi-technicals
59.2
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
rsi-technicals
51.7
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TCMD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TCMD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.90% | 74.80% | +1.10 | TCMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.10% | 20.70% | -3.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.9x | 15.3x | -0.40 | TCMD | /valuation <GO> |
| Free Cash Flow Yield | 7.34% | 3.42% | +3.92 | TCMD | /fcf-yield <GO> |
| Operating Margin | 8.90% | 34.30% | -25.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 5.80% | 28.10% | -22.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 12.50% | 1.30% | +11.20 | TCMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.38 | 5.19 | +3.19 | TCMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TCMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 59.2 | 51.7 | +7.50 | TCMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.3x | 18.4x | +5.90 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $550.7M | $361.02B | -$360.47B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TCMD REV | MRK REV | TCMD GROSS % | MRK GROSS % | TCMD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $329.5M | $65.01B | 75.9% | 74.8% | $40.4M | $12.36B |
| FY 2024 | $293.0M | $64.17B | 74.0% | 76.3% | $38.3M | $18.10B |
| FY 2023 | $274.4M | $60.12B | — | — | $35.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TCMD // BETA —
MRK // BETA 0.92